Drs. Fizazi, Wallis on Updated Data from TALAPRO-2
Karim Fizazi, MD, PhD, Institute Gustave Roussy, and Christopher Wallis, MD, PhD, University of Toronto, detail the latest updates regarding the phase 3 study of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line treatment for patients with mCRPC harboring homologous recombination repair gene alterations. View more ASCO 2023 videos. ...

Latest News

Editorial Advisory Board

Expert Interviews

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Conference Coverage

Live meeting highlights

Brian Rini, MD, FASCOASCO 2023 | June 5, 2023
Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.
View More
Oncology BrothersASCO 2023 | June 5, 2023
The Oncology Brothers chat with Dr. Wallis on PARP inhibitors as well as neoadjuvant IO and EV for bladder cancer.
Zachary BessetteASCO 2023 | June 5, 2023
dd-MVAC provides a better OS at 5 years compared with GC in the perioperative setting for patients with MIBC.
Zachary BessetteASCO 2023 | June 5, 2023
Updated PFS data was presented for the first phase 3, randomized trial to test the benefit of ICI rechallenge in mRCC.

Video Insights

Clinical discussions with experts in the field